DOCSLIB.ORG

Local Anaesthetics Combined with Vasoconstrictors in Patients with Cardiovascular Disease Undergoing Dental Procedures: Systematic Review and Meta-­Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Local Anaesthetics Combined with Vasoconstrictors in Patients with Cardiovascular Disease Undergoing Dental Procedures: Systematic Review and Meta-­Analysis Open access Original research BMJ Open: first published as 10.1136/bmjopen-2020-044357 on 15 July 2021. Downloaded from Local anaesthetics combined with vasoconstrictors in patients with cardiovascular disease undergoing dental procedures: systematic review and meta- analysis Caio Chaves Guimaraes ,1 Luciane Cruz Lopes ,2 Cristiane de Cássia Bergamaschi ,2 Juliana Cama Ramacciato,3 Marcus Tolentino Silva ,2 Jimmy de Oliveira Araújo,1 Natalia Karol de Andrade,1 Rogério Heládio Lopes Motta 3 To cite: Guimaraes CC, ABSTRACT Strengths and limitations of this study Lopes LC, Bergamaschi CdC, Objectives There is a lack of evidence about the use of et al. Local anaesthetics local anaesthetics (LAs) in patients with cardiovascular ► This review was conducted with methodological combined with vasoconstrictors diseases (CVD) in dental procedures. Thus, this study in patients with cardiovascular rigour, including assessment of the risk of bias and evaluated the safety of using LA with vasoconstrictor to disease undergoing dental the quality of evidence; such information is not determine the risk of cardiovascular events in patients procedures: systematic review available in previous systematic reviews related to with CVD. and meta- analysis. BMJ Open the subject. 2021;11:e044357. doi:10.1136/ Design Systematic review and meta- analysis. ► This study has explicit eligibility criteria, priority Methods We have searched in Cochrane Central Register bmjopen-2020-044357 of primary and secondary outcomes, comprehen- of Controlled Trials (CENTRAL), MEDLINE (via Ovid), Prepublication history and sive and extensive search in the databases, with ► EMBASE (via Ovid), Healthstar (via Ovid), CINAHL, Web of additional supplemental material independent and peer reviews for each study and Science and ClinicalTrials. gov for randomised controlled for this paper are available use of Grading of Recommendations Assessment, trials (RCTs) up to January 2020. We have included RCTs online. To view these files, Development and Evaluation to assess the quality of http://bmjopen.bmj.com/ involving adults with CVD within two groups: intervention please visit the journal online. the evidence and the strength of recommendation group with LA with vasoconstrictor and control group To view these files, please visit for the outcomes included in the meta-analysis. the journal online (http:// dx. doi. with LA without vasoconstrictor. The primary outcomes ► The primary studies included were a limiting factor org/ 10. 1136/ bmjopen- 2020- assessed were death, mortality by a specific cause, for the findings of this review due to methodological 044357). stroke, acute myocardial infarction, hospitalisation, pain, bias observed in the included randomised controlled bleeding and arrhythmias. The secondary outcomes were Received 21 September 2020 trials, as well as the differences observed in the ST segment depression, anxiety, adverse effects and Accepted 15 June 2021 types of cardiovascular diseases, types and dosages changes in haemodynamic parameters. The data were of local anaesthetics and vasoconstrictors. pooled using random effects meta-analyses and the on September 26, 2021 by guest. Protected copyright. confidence in the estimates was verified using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). INTRODUCTION Results Ten RCTs (n=478 participants) were included. Cardiovascular diseases (CVD) are one of the Most of them had a high risk of bias. There were causes of most premature deaths worldwide, more cases of pain and bleeding in groups without representing 31% of all deaths. It is estimated vasoconstrictor. Meta- analysis demonstrated a decrease in the systolic blood pressure with the use of LA with that in 2012 CVD were the main cause of death vasoconstrictor (standard mean difference −0.95, 95% CI in the world with approximately 17.5 million © Author(s) (or their −1.35 to −0.55) after procedure. Overall, for the other deaths. In 2002, three- quarters of CVD deaths employer(s)) 2021. Re- use occurred in low-income or middle-income permitted under CC BY-NC. No outcomes assessed there was no statistical difference. The commercial re- use. See rights quality of evidence was considered low according to the countries. CVD comprises essential hyper- and permissions. Published by GRADE profile. tension, rheumatic heart diseases, ischaemic BMJ. Conclusions The results suggest that the use of LA with heart diseases, cerebrovascular diseases, heart For numbered affiliations see vasoconstrictors (epinephrine in low doses) is safe in inflammatory diseases and so forth.1 end of article. patients with some types of CVD. However, the low quality In the dental office, the presence of of evidence demonstrated that literature needs further patients with complex diseases such as CVD Correspondence to studies in order to confirm these results. is increasingly common. These patients have Caio Chaves Guimaraes; Protocol registration PROSPERO (CRD42016045421). drcaio_ cg@ hotmail. com access to better treatments and medications, Guimaraes CC, et al. BMJ Open 2021;11:e044357. doi:10.1136/bmjopen-2020-044357 1 Open access BMJ Open: first published as 10.1136/bmjopen-2020-044357 on 15 July 2021. Downloaded from http://bmjopen.bmj.com/ Figure 1 Flow chart for literature search and study selection. CVD, cardiovascular disease; RCT, randomised controlled trial. which makes it possible to perform treatment in private These systemic adverse effects are linked to inadequate dental clinics that previously was only executed by special- procedures such as intravascular injection, high-dose ised hospitals.2 3 However, careful evaluations should be injections, drug interactions or instant absorption of the on September 26, 2021 by guest. Protected copyright. conducted before beginning dental treatment in patients anaesthetic agent when it is injected into an extremely with CVD in order to control stress and mainly to block vascular area that could induce adverse cardiovascular nerve transmission of pain, thereby minimising tran- effects, especially in patients with CVD.3 8–10 sient episodes that may trigger negative cardiovascular Another factor for adverse effects is the concentration outcomes.3 used in LAs. Currently, a greater dilution of the vasocon- The use of local anaesthetics (LAs) and analgesics can strictor is recommended, mostly used at a concentration control pain, while sedatives control the anxiety during of 1:100 000 for surgical procedures and, for other proce- dental procedures.3 4 However, the use of LA has been the dures, with a dilution of up to 1:200 000.2 6 Nevertheless, baseline of pain control for dental procedures for several for long and/or surgical procedures, LAs without vasocon- decades.5 6 strictor do not offer a satisfactory anaesthetic duration, LAs are combined with vasoconstrictors to increase which can cause pain resulting in systemic endogenous duration of anaesthetic effect, reduce systemic toxicity release of catecholamines (particularly norepinephrine) and optimise soft tissue haemostasis.6 However, despite the and causing negative cardiovascular outcomes.11–13 beneficial properties of vasoconstrictors when combined A previous study reported that the stress- induced with LAs, dental professionals are concerned about the release of catecholamines could be >10 times greater than adverse effects associated with the vasoconstrictor, mainly the basal level.14 In stressful situations, such as pain and with epinephrine, which is the most used vasoconstrictor anxiety, the released endogenous catecholamines may also in dentistry.2 7 reach concentrations higher than the low epinephrine 2 Guimaraes CC, et al. BMJ Open 2021;11:e044357. doi:10.1136/bmjopen-2020-044357 Open access BMJ Open: first published as 10.1136/bmjopen-2020-044357 on 15 July 2021. Downloaded from METHODS AND ANALYSES The systematic review was performed according to the recommendations specified in the Cochrane Handbook for Interventional Reviews and reported according to the Preferred Reporting Items for Systematic Reviews and Meta- Analyses statement.18 Protocol and registration The protocol of this systematic review was registered on the PROSPERO—International Prospective Register of System- atic Reviews (registration number CRD42016045421). Eligibility criteria Inclusion criteria Patients Adult patients with CVD (essential hypertension, rheu- matic heart diseases, ischaemic heart diseases, cerebrovas- cular diseases, and heart inflammatory diseases).1 Interventions One arm wherein patients received LA with vasocon- strictors compared with another arm wherein patients received LAs without vasoconstrictors. Procedures Patients who undergo tooth extraction, dental resto- rations, treatment and periodontal surgery, among others. Figure 2 Risk of bias summary: review authors’ judgements. Type of study Considering that observational studies increase the risk concentrations used in dental LA.14 15 Thus, the literature of bias to answer this question, the study design that can generate high quality evidence, according to the recommends using the lowest effective concentration of http://bmjopen.bmj.com/ epinephrine as possible for patients with CVD, both for evidence hierarchy, would be the randomised controlled dermatological and dental procedures.9 13 A few decades trials (RCTs). We include two types of RCT designs. In the ago, the maximum dose of epinephrine in patients with first type, patients are randomised to receive either LAs cardiovascular disease was set at up to
Load more

Recommended publications
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • List of Pharamaceutical Peptides Available from ADI
    List of Pharamaceutical Peptides Available from ADI ADI has highly purified research grade/pharma grade pharmaceutical peptides available for small research scale or in bulk (>Kg scale). (See Details at the website) http://4adi.com/commerce/catalog/spcategory.jsp?category_id=2704 Catalog# Product Description Catalog# Product Description PP-1000 Abarelix (Acetyl-Ser-Leu-Pro-NH2; MW:1416.06) PP-1410 Growth Hormone-releasing factor, GRF (human) PP-1010 ACTH 1-24 (Adrenocorticotropic Hormone human) Acetate PP-1420 Hexarelin PP-1020 Alarelin Acetate PP-1430 Histrelin Acetate PP-1030 Angiotensin PP-1440 Lepirudin PP-1040 Angiotensin II Acetate PP-1450 Leuprolide PP-1050 Antide Acetate PP-1460 Leuprorelin Acetate PP-1060 Argipressin Acetate PP-1470 Lipopeptide Acetate PP-1070 Argireline Acetate PP-1480 Lypressin PP-1080 Atosiban Acetate PP-1490 Lysipressin Acetate PP-1090 Aviptadil PP-1500 Matrixyl Acetate PP-1100 Bivalirudin Trifluoroacetate PP-1510 Melanotan I, Acetate PP-1110 Buserelin acetate PP-1520 Melanotan II, MT-II, Acetate PP-1120 Copaxone acetate (Glatiramer acetate) PP-1530 Mechano Growth Factor, MGF, TFA PP-1130 Carbetocin acetate PP-1540 Nafarelin Acetate PP-1140 Cetrorelix Acetate PP-1550 Nesiritide Acetate PP-1150 Corticotropin-releasing factor, CRF (human, rat) Acetate PP-1560 Octreotide Acetate PP-1160 Corticotropin-releasing factor, CRF (ovine) PP-1570 Ornipressin Acetate Trifluoroacetate PP-1580 Oxytocin Acetate PP-1170 Deslorelin Acetate PP-1590 Palmitoyl Pentapeptide PP-1180 Desmopressin Acetate PP-1610 Pentagastrin Ammonium
    [Show full text]
  • Queensland Health List of Approved Medicines
    Queensland Health List of Approved Medicines Drug Form Strength Restriction abacavir * For use in accord with PBS Section 100 indications * oral liquid See above 20 mg/mL See above tablet See above 300 mg See above abacavir + lamivudine * For use in accord with PBS Section 100 indications * tablet See above 600 mg + 300 mg See above abacavir + lamivudine + * For use in accord with PBS Section 100 indications * zidovudine tablet See above 300 mg + 150 mg + 300 mg See above abatacept injection 250 mg * For use in accord with PBS Section 100 indications * abciximab (a) Interventional Cardiologists for complex angioplasty (b) Interventional and Neuro-interventional Radiologists for rescue treatment of thromboembolic events that occur during neuroendovascular procedures. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * injection See above 10 mg/5 mL See above abiraterone For use by medical oncologists as per the PBS indications for outpatient and discharge use only tablet See above 250 mg See above 500 mg See above acamprosate Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence. enteric tablet See above 333 mg See above acarbose For non-insulin dependent diabetics with inadequate control despite diet; exercise and maximal tolerated doses of other anti-diabetic agents tablet See above 50 mg See above 100 mg See above acetazolamide injection 500 mg tablet 250 mg acetic acid ear drops 3% 15mL solution 2% 100mL green 3% 1 litre 6% 1 Litre 6% 200mL Generated on: 30-Aug-2021 Page 1 of 142 Drug Form Strength Restriction acetylcysteine injection For management of paracetamol overdose 2 g/10 mL See above 6 g/30 mL See above aciclovir cream Infectious disease physicians, haematologists and oncologists 5% See above eye ointment For use on the advice of Ophthalmologists only.
    [Show full text]
  • (19) World Intellectual Property Organization International Bureau
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 7 September 2007 (07.09.2007) PCT W O 2007/100775 A2 (51) International Patent Classification: Not classified AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, HI, (21) International Application Number: GB, GD, GE, Gi, GM, GI, HN, HR, HU, ID, IL, IN, IS, PCT/US2007/004959 JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, (22) International Filing Date: MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, 27 February 2007 (27.02.2007) RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (26) Publication Language: English (84) Designated States (unless otherwise indicated,for every kind of regional protection available): ARIPO (BW, GI, (30) Priority Data: GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 60/777,190 27 February 2006 (27.02.2006) US ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), 60/858,186 9 November 2006 (09.11.2006) US European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, (71) Applicant and RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, (72) Inventor: MICHALOW, Alexander [US/US]; 1255 GN, GQ, GW, ML, MR, NE, SN, ID, IG).
    [Show full text]
  • CUSTOMS TARIFF - SCHEDULE 99 - I
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2016 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • Ep 2326341 B1
    (19) & (11) EP 2 326 341 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 38/11 (2006.01) 04.07.2012 Bulletin 2012/27 (86) International application number: (21) Application number: 09788312.8 PCT/NL2009/050542 (22) Date of filing: 09.09.2009 (87) International publication number: WO 2010/030180 (18.03.2010 Gazette 2010/11) (54) Oxytocin formulations and uses thereof Oxytocin-Formulierungen und ihre Verwendungen Formulations d’oxytocine et leur utilisations (84) Designated Contracting States: • TRISSEL ET AL: INTERNATIONAL JOURNAL OF AT BE BG CH CY CZ DE DK EE ES FI FR GB GR PHARMACEUTICAL COMPOUNDING, vol. 10, HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL 2006, pages 156-158, XP002513262 cited in the PT RO SE SI SK SM TR application • BOOTHBY ET AL: "Extended stability of oxytocin (30) Priority: 09.09.2008 EP 08163932 in Ringer’s lactate solution at 4° and 25°C" HOSPITAL PHARMACY, vol. 41, 2006, pages (43) Date of publication of application: 437-441, XP002513263 01.06.2011 Bulletin 2011/22 • DE GROOT ET AL: "Oxytocin and desamino- oxytocin tablets are not stable under simulated (73) Proprietor: Rijksuniversiteit Groningen tropical conditions" JOURNAL OF CLINICAL 9712 CP Groningen (NL) PHARMACY AND THERAPEUTICS, vol. 20, 1995, pages 115-119, XP002513264 cited in the (72) Inventors: application • AMORIJ, Jean-Pierre • WYTTENBACH ET AL: "Interactions of the NL-1544 PA Zaandijk (NL) hormone oxytocin with divalent metal ions" • AVANTI, Christina JOURNAL OF THE AMERICAN CHEMICAL NL-9725 AN Groningen (NL) SOCIETY, vol.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Our Generic Api Portfolio
    OUR GENERIC API PORTFOLIO: ACTH (Corticotropin) Atosiban Bivalirudin Calcitonin Carbetocin Deslorelin Desmopressin Eptifibatide Exenatide Felypressin Glucagon, HCl Gonadorelin Acetate / HCl GRF (1-29) Amide Lanreotide Leuprolide Liraglutide Octreotide PTH (1-34) / Teriparatide Somatostatin Triptorelin Vasopressin, 8-L-Arginine The PolyPeptide Group manufactures a range of peptide-based generic APIs at commercial scale for the human and veterinary market. For any inquiries or questions regarding our portfolio, products and prices, please contact one of our sales representatives: PolyPeptide Group in Europe PolyPeptide Group in USA PolyPeptide Group in Asia Tel: +46 40 366 200 Tel: +1 310 782 3569 Tel +91 251 398 1914 Email: [email protected] Email: [email protected] Email: [email protected] www.polypeptide.com THE ULTIMATE PEPTIDE PARTNER OUR GENERIC API PORTFOLIO Products under Patent are not for ultimate sale in the countryProducts under Patent laws will be to the account of Purchaser. where patent has not expired. All liability for violation of Patent Peptide name: Clinical use/ Therapeutic Areas: DMF Availability : Manufacturing site: ACTH Clinical use: Various autoimmune diseases (multiple (Corticotropin) sclerosis relapse, infantile spasms etc.) Late development India Therapeutic Areas: Endocrinology, musculoskeletal Atosiban Clinical use: Labor suppressant to halt or delay premature labor Sweden Therapeutic Areas: Obstetrics, gynecology Bivalirudin Clinical use: Anticoagulant in conjunction
    [Show full text]
  • Synthetic Peptides by Dr Olga Kolaj-Robin
    03/02/2017 European Pharmacopoeia Training Session on Biologicals 7-8 February 2017, Strasbourg A guide through monograph sections with emphasis on synthetic peptides Olga Kolaj-Robin, PhD Scientific Officer, European Pharmacopoeia Department 1 Olga KOLAJ-ROBIN ©2017 EDQM, Council of Europe. All rights reserved. Basis for the elaboration of monographs Products of proven safety, evaluated and approved by competent authorities of Member States; Impurity profiles for existing, approved synthetic routes; Use of robust, validated analytical methods; Technical guides 2 Olga KOLAJ-ROBIN ©2017 EDQM, Council of Europe. All rights reserved. 1 03/02/2017 Individual and General monographs are complementary Individual Relevant General monographs monograph(s) 3 Olga KOLAJ-ROBIN ©2017 EDQM, Council of Europe. All rights reserved. Synthetic peptides • Product of chemical synthesis; • Molecular mass typically below 5000 Da; • May contain chemical structures that do not occur naturally in proteins or peptides; • Generally sufficiently characterised by physico-chemical tests; bioassay not necessary. 4 Olga KOLAJ-ROBIN ©2017 EDQM, Council of Europe. All rights reserved. 2 03/02/2017 Ph. Eur. portfolio for synthetic peptides • (0471) Calcitonin (salmon) • (1077) Buserelin • (0644) Tetracosactide * • (1144) Protirelin • (0712) Desmopressin • (1442) Leuprorelin • (0779) Oxytocin conc. solution • (1634) Felypressin • (0780) Oxytocin * • (1636) Goserelin • (0827) Gonadorelin acetate * • (2646) Terlipressin • (0949) Somatostatin * * under revision In development: • (2414) Octreotide (Phpa 28.4) • (3056) Lanreotide • (3054) Atosiban • (3057) Glatiramer • (3055) Triptorelin 5 Olga KOLAJ-ROBIN ©2017 EDQM, Council of Europe. All rights reserved. Synthetic peptideMONOGRAPH SECTION rDNA product Version date Title INN Formula molecular and graphic Relative mass CAS number Definition • chemical nomenclature • salt form • additives (e.g.
    [Show full text]